Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study
Matthew Orton(Royal Marsden NHS Foundation Trust), Dow‐Mu Koh(Royal Marsden NHS Foundation Trust), Simon Doran(Institute of Cancer Research), Joshua Shur(Royal Marsden NHS Foundation Trust), Samra Turajlic(Royal Marsden NHS Foundation Trust), José I. López(BioCruces Health research Institute), Francesca Comito(Azienda USL di Bologna), Christina Messiou(Institute of Cancer Research), Evan Hann(University of Oxford), James Larkin(Trinity College Dublin), Scott T.C. Shepherd(Royal Marsden NHS Foundation Trust), Charlotte Spencer(The Francis Crick Institute), Hannah Warren(Guy's and St Thomas' NHS Foundation Trust), Derfel ap Dafydd(Royal Marsden Hospital), Víctor Albarrán-Artahona(Institut Gustave Roussy)
Cited by 19
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k